Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Tratamento melhorado para pacientes com terapia de opióides de longo prazo para dor não-câncer na atenção primária (Opi-Prim)

25 de setembro de 2026 atualizado por: Thomas Kempen, Uppsala County Council, Sweden

Tratamento aprimorado para pacientes com terapia de opióides de longo prazo para dor não-câncer na atenção primária (OPI-PRIM)

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

  • Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
  • Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
  • Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

Tipo de estudo

Intervencional

Inscrição (Estimado)

110

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Gävleborg County
      • Gävle, Gävleborg County, Suécia
        • Ainda não está recrutando
        • Region Gävleborg
        • Contato:
    • Södermanland County
      • Strängnäs, Södermanland County, Suécia
        • Ainda não está recrutando
        • Region Sörmland
        • Contato:
    • Uppsala County
      • Uppsala, Uppsala County, Suécia
        • Recrutamento
        • Region Uppsala
        • Contato:
    • Örebro County
      • Örebro, Örebro County, Suécia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
  • Able to speak Swedish or English

Exclusion Criteria:

  • Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
  • No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
  • Using their opioids for cancer pain

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Control

Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

Comparador Ativo: Intervention

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pain interference
Prazo: The primary outcome measure will be the difference in mean pain interference after 6 months.

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

The primary outcome measure will be the difference in mean pain interference after 6 months.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Pain intensity
Prazo: After 3, 6 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse

After 3, 6 and 12 months
Symptoms of depression
Prazo: After 3, 6 and 12 months

Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Symptoms of anxiety
Prazo: After 3, 6 and 12 months

Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Patient satisfaction
Prazo: After 3, 6 and 12 months

Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse

After 3, 6 and 12 months
Quality of life according to the 5-level EuroQol 5D
Prazo: After 3, 6 and 12 months

Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.

After 3, 6 and 12 months
Opioid use
Prazo: After 3, 6 and 12 months

Measured with as morphine equivalents: in mg.

After 3, 6 and 12 months
Symptoms of withdrawal
Prazo: After 3, 6 and 12 months

Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse

After 3, 6 and 12 months
Pain interference
Prazo: After 3 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

After 3 and 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de março de 2025

Conclusão Primária (Estimado)

30 de junho de 2028

Conclusão do estudo (Estimado)

31 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

26 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de fevereiro de 2025

Primeira postagem (Real)

4 de março de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Opi-Prim

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .